Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown significant growth in both share volume and fund size since its inception, indicating strong investor interest and market performance [1][2]. Group 1: Fund Performance - As of October 31, 2024, the Hong Kong Innovative Drug ETF (159567) closed with a gain of 5.46% and a trading volume of 3.327 billion yuan [1]. - The fund's share volume increased by 1968.65% from 3.95 million shares at the end of 2023 to 81.79 million shares by October 30, 2024 [1]. - The fund's size grew by 1650.00%, from 378 million yuan to 6.612 billion yuan during the same period [1]. Group 2: Liquidity - Over the last 20 trading days, the cumulative trading amount for the fund reached 23.202 billion yuan, with an average daily trading amount of 1.16 billion yuan [1]. - Year-to-date, the cumulative trading amount for the fund is 234.346 billion yuan, averaging 1.172 billion yuan per day over 200 trading days [1]. Group 3: Fund Management - The current fund manager, Ma Jun, has managed the Hong Kong Innovative Drug ETF (159567) since its inception, achieving a return of 64.72% during the management period [2]. - The fund's top holdings include companies such as BeiGene, CanSino Biologics, Innovent Biologics, and others, with significant percentages of the portfolio allocated to these stocks [2].

Core Insights - On October 31, 2025, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) ranked as the top three companies by trading volume in the southbound trading of the Stock Connect, with trading volumes of 58.52 billion, 43.31 billion, and 30.98 billion respectively [1][2] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) also held the top three positions, with trading volumes of 43.07 billion, 28.25 billion, and 26.32 billion respectively [1][2] Southbound Trading Highlights - **Top Active Companies in Southbound Trading (Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 58.52 billion, net buy of -4.81 billion [2] - SMIC (00981): Trading amount of 43.31 billion, net buy of -78.06 million [2] - Tencent Holdings (00700): Trading amount of 30.98 billion, net buy of -1.72 billion [2] - Xiaomi Group-W (01810): Trading amount of 19.39 billion, net buy of +5.56 billion [2] - Huahong Semiconductor (01347): Trading amount of 18.61 billion, net buy of -1.67 billion [2] - **Top Active Companies in Southbound Trading (Shenzhen-Hong Kong Stock Connect)** - Alibaba-W (09988): Trading amount of 43.07 billion, net buy of +1.15 billion [2] - SMIC (00981): Trading amount of 28.25 billion, net buy of -6.34 billion [2] - Tencent Holdings (00700): Trading amount of 26.32 billion, net buy of -10.47 billion [2] - Huahong Semiconductor (01347): Trading amount of 11.90 billion, net buy of -3.07 billion [2] - Xiaomi Group-W (01810): Trading amount of 11.13 billion, net buy of +904.39 million [2]

Macro Dynamics - In September, the bond market issued a total of 81,027.8 billion yuan in various bonds, including 14,904.9 billion yuan in government bonds, 8,519.1 billion yuan in local government bonds, 11,741.0 billion yuan in financial bonds, 13,407.3 billion yuan in corporate credit bonds, 365.7 billion yuan in credit asset-backed securities, and 31,627.8 billion yuan in interbank certificates of deposit [2] - In September, China's foreign exchange market had a total transaction volume of 26.87 trillion yuan (approximately 3.78 trillion USD), with the interbank market accounting for 22.44 trillion yuan (approximately 3.16 trillion USD) [3] - In the first three quarters, the revenue of large-scale internet and related service enterprises in China reached 14,420 billion yuan, showing a year-on-year growth of 2.8% [4][5] Financial Institutions - China Taiping announced the sale of minority stakes in four companies for a total consideration of 6.5 billion yuan [8] - Hangzhou Bank received approval to issue capital instruments not exceeding 40 billion yuan [9] Market Data - On October 31, A-shares saw a collective decline, with the Shanghai Composite Index down 0.81%, the Shenzhen Component down 1.14%, and the ChiNext Index down 2.31% [11] - The financing balance in the two markets decreased by 7.392 billion yuan, with the Shanghai Stock Exchange reporting a balance of 12,535.78 billion yuan and the Shenzhen Stock Exchange reporting 12,196.92 billion yuan [12] Company Dynamics - China National Petroleum Corporation announced the resignation of Zhou Song as the chairman of the supervisory board [14] - InSai Group decided to terminate a major asset restructuring plan due to changes in the external environment [15] - Tianqi Co., Ltd. signed a strategic cooperation framework agreement with Foxconn Automotive to deploy at least 2,000 embodied intelligent robots over the next five years [17] - Li Auto announced a recall of 11,411 units of the MEGA 2024 electric vehicle due to potential safety hazards [18] - Qingyue Technology is under investigation by the China Securities Regulatory Commission for suspected false financial reporting [19]

| 代码 | 简称 | 收盘价 (港元) | 准庆幅 (%) | 净买入金额 (亿港元) | | | --- | --- | --- | --- | --- | --- | | 1810.HK | 小米集团-W | 43.2 | -2.17 | 6.46 | . | | 3690.HK | 美团-W | 102.0 | -0.39 | 4.65 | . | | 1530.HK | 三生制药 | 30.8 | 11.27 | 0.75 | . | | 0883.HK | 中国海洋石油 | 19.77 | -1.25 | 0.35 | . | | 1635.HK | 大众公用 | 4.41 | 4.01 | 0.23 | | | 1772.HK | 赣锋锂业 | 51.3 | -5.44 | -0.27 | . | | 9992.HK | 泡泡玛特 | 221.6 | -3.57 | -2.94 | . | | 0763.HK | 中兴通讯 | 32.9 | -6.16 | -3.07 | = | | 9988.HK | 阿里巴巴-W | 165.1 | -4.07 | -3.66 | | | 1347.HK | ...

个股方面，比亚迪股份跌3.45%，小米集团跌2.17%，美团跌0.39%，滴普科技涨15.02%，三生制药涨 11.27%，工商银行跌0.50%，中国石油股份涨0.63%，赣锋锂业跌5.44%，阅文集团跌3.69%，小鹏汽车 跌1.36%，东方电气跌5.52%，汇丰控股涨0.09%，泡泡玛特跌3.57%，长实集团涨0.10%。 成交额前三的个股中，阿里巴巴跌4.07%，成交超162亿港元；腾讯控股跌3.38%，成交超130亿港元； 中芯国际跌5.30%，成交超82亿港元。 新华财经香港10月31日电（记者林迎楠）31日港股主要指数低开低走，截至收盘，恒生指数下跌1.43% 至25906.65点，恒生科技指数下跌2.37%至5908.08点，国企指数下跌1.91%至9168.58点。 当日恒指低开19.68点，开报26263.01点，开盘先在高点短暂震荡，后一路下跌，最终恒指跌376.04点， 主板成交超2576亿港元。截至收盘，上涨股票777只，下跌1434只，收平996只。当日，港股通（南向） 净流入超过87亿港元。 整体来看，多数板块下跌，生物医药、创新药等股多为上涨，银行、保险、石油与天然气等股有涨有 ...

Core Insights - The innovative drug sector experienced a significant surge in stock prices, driven by news of the national medical insurance negotiation, with companies like Sanofi and Sihuan Pharmaceutical seeing their stocks hit the daily limit increase [1] - The introduction of the "Commercial Insurance Innovative Drug Directory" mechanism is expected to enhance the market for innovative drugs, allowing for better pricing and payment structures [1] Group 1: National Medical Insurance Negotiation - The 2025 National Medical Insurance negotiation commenced on October 30, introducing the "Commercial Insurance Innovative Drug Directory" for the first time [1] - This directory will include innovative drugs that are not yet part of the basic medical insurance but have high clinical value and significant patient benefits [1] - The development of commercial insurance is deemed essential, with the directory providing guidance for market pricing and optimizing drug price formation mechanisms [1] Group 2: Company-Specific Developments - On October 30, Pfizer registered two global Phase III clinical trials for the PD-1/VEGF bispecific antibody SSGJ-707, developed by Sihuan Pharmaceutical and Sanofi [2] - Pfizer will pay an upfront fee of $1.25 billion and up to $4.8 billion in milestone payments for the global development, production, and commercialization rights of SSGJ-707 [2] - Sanofi holds a 30% stake in the SSGJ-707 project, while Sihuan Pharmaceutical holds 70%, indicating potential future revenue from milestone payments for Sanofi [2] Group 3: Financial Performance - In Q3, Sanofi reported a revenue of 474 million yuan, a year-on-year increase of 38.27%, and a net profit of 209 million yuan, up 101.41% [3] - For the first three quarters, the company achieved a revenue of 1.116 billion yuan, reflecting an 18.80% year-on-year growth, and a net profit of 399 million yuan, a 71.15% increase [3] - The growth in revenue is attributed to licensing income from collaboration projects and an increase in CDMO business, alongside improved management efficiency and reduced expense ratios [3]

Core Insights - The Hong Kong stock market saw a net inflow of 87.19 billion HKD from northbound trading on October 31, with 57.72 billion HKD from the Shanghai Stock Connect and 29.47 billion HKD from the Shenzhen Stock Connect [1] Group 1: Net Inflows and Outflows - The most bought stocks included Xiaomi Group-W (01810), Meituan-W (03690), and Sanofi Pharmaceutical (01530) [1] - The most sold stocks included Tencent (00700), SMIC (00981), and Hua Hong Semiconductor (01347) [1] Group 2: Stock Performance Details - Xiaomi Group-W (01810) had a net inflow of 6.46 billion HKD, supported by optimistic forecasts for its smartphone and electric vehicle businesses [5] - Meituan-W (03690) received a net inflow of 4.64 billion HKD, with news of its international food delivery brand Keeta launching operations in Brazil [5] - Sanofi Pharmaceutical (01530) saw a net inflow of 754.6 million HKD, following the registration of a new cancer treatment in clinical trials [5] Group 3: Notable Sell-offs - Tencent (00700) experienced a net outflow of 12.19 billion HKD, amid increased short-selling activities in the market [7] - SMIC (00981) faced a net outflow of 7.11 billion HKD, as the semiconductor sector reacted to potential changes in AI chip export policies [8] - Hua Hong Semiconductor (01347) had a net outflow of 4.73 billion HKD, reflecting broader trends in the chip industry [8]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling 1.43% to 25,906.65 points, and the Hang Seng Technology Index dropping 2.37% to 5,908.08 points. The total trading volume for the day was 257.61 billion HKD [1] - For the month, the Hang Seng Index decreased by 3.53%, the Hang Seng China Enterprises Index fell by 4.05%, and the Hang Seng Technology Index saw a decline of 8.62% [1] Blue-Chip Stocks Performance - AIA Group (01299) rose by 3.07% to 75.45 HKD, contributing 37.56 points to the Hang Seng Index. The company reported a 25% year-on-year increase in new business value to 1.476 billion USD for Q3 2025 [2] - Other notable blue-chip stocks included Hansoh Pharmaceutical (03692) up 4.21%, and China Biologic Products (01177) up 2.91%. Conversely, SMIC (00981) fell by 5.3%, and Xinyi Solar (00968) dropped by 5.04% [2] Sector Highlights - The innovative drug sector saw gains, with 3SBio (01530) increasing by 11.27% and Innovent Biologics (01801) rising by 7.81%. The sector is benefiting from the upcoming National Medical Insurance negotiations and a significant increase in licensing deals for innovative drugs [3][4] - AI application stocks also showed positive movement, with Huya Technology (01860) rising by 7.86% and Fourth Paradigm (06682) increasing by 2.76% [4][5] Quarterly Earnings - Several pharmaceutical companies reported strong Q3 earnings, including Heng Rui Medicine with a net profit of 5.751 billion CNY, up 24.5% year-on-year, and Innovent Biologics with over 3.3 billion CNY in total product revenue, reflecting a 40% growth [4][6] - Spring Medical (01858) reported a 109.51% increase in revenue to 268 million CNY for Q3, while China CNR Corporation (01766) saw a 10.62% decline in net profit [6] Notable Stock Movements - Dipei Technology (01384) surged by 15.02% to 113.7 HKD, marking a 300% increase since its IPO, driven by a 118.4% revenue growth in the first half of the year [7] - China Shengmu (01432) rose by 13.11% to 0.345 HKD, following a strategic shareholding increase by Modern Dairy [8] - China Duty Free Group (01880) increased by 5.78% to 66.8 HKD, supported by new policies aimed at boosting consumption through duty-free stores [9] - Huahao Zhongtian Pharmaceutical (02563) fell by 33.93% to 3.35 HKD, following a significant share unlock event [10] - Air China (00753) dropped by 6.55% to 5.71 HKD, with a reported net profit decline of 11.31% in Q3 [11]

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 1.43% to close below 26,000 points, marking three consecutive days of decline [1] - The cumulative decline for the Hang Seng Index in October is 3.35%, while the National Index and Hang Seng Tech Index fell by 4.05% and 8.62%, respectively [2] Sector Performance - Major technology stocks dragged down market sentiment, with significant declines in large financial stocks, semiconductor stocks, and various other sectors including military, automotive, coal, gold, real estate, aviation, and solar energy [3] - The biotechnology sector saw multiple catalysts igniting interest, leading to gains in education, home appliance, and gaming stocks [3] Notable Stock Movements - Alibaba dropped by 4%, Tencent fell over 3%, and other tech stocks like Kuaishou, Baidu, JD.com, and Xiaomi also saw declines exceeding 2% [4] - Financial stocks such as Everbright Securities and Huatai Securities experienced declines over 5%, while major banks also reported losses [5][6] Specific Stock Highlights - The automotive sector saw declines with BYD and Great Wall Motors dropping over 3%, while semiconductor stocks like Huahong Semiconductor and ZTE fell by over 6% [9][10] - The pharmaceutical and innovative drug sectors performed well, with companies like 3SBio and Innovent Biologics seeing significant gains [11] Capital Inflows - There was a notable net inflow of capital from southbound trading, with over 8.719 billion HKD in net purchases [12] Future Outlook - Analysts suggest that the current market conditions may favor sectors such as raw materials, export-oriented industries, and those benefiting from RMB appreciation, including aviation and paper manufacturing [14]

10月31日，港股10月收官。香港恒生指数报收25906.65点，跌1.43%，恒生科技指数报收5908.08点，跌2.37%。 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | 成交额 | | --- | --- | --- | --- | --- | --- | | HSI | 恒生指数 | 25906.65c -376.04 | | -1.43% | 2576亿 | | HSTECH 恒生科技 | | 5908.08c -143.68 | | -2.37% | 741亿 | | HSBIO 恒生生物科技 | | 15692.71c 345.23 | | 2.25% | 170亿 | | HSCEI | 恒生中国企业指数 | 9168.58c -178.28 - -1.91% | | | 958亿 | | HSCl | 恒生综合指数 | 3996.49 c -64.32 -1.58% | | | 1886亿 | 医药股上涨，三生制药涨超11%，信达生物涨超7%，复星医药涨超6%。 编辑丨瑜见 大型科技股普遍走低，阿里巴巴跌超4%，腾讯控股跌超3%，京东集团、百度集团跌超2%。 芯片股领跌，华虹半导体 ...